Benjamin J Ansell1, Gregg C Fonarow, Alan M Fogelman. 1. Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA. bansell@mednet.ucla.edu
Abstract
PURPOSE OF REVIEW: This review addresses how, in atherosclerosis or systemic inflammation, HDL can lose its usual atheroprotective characteristics and even paradoxically assume proinflammatory properties. RECENT FINDINGS: Specific chemical and structural changes within HDL particles can impede reverse cholesterol transport, enhance oxidation of LDL, and increase vascular inflammation. HDL may be viewed as a shuttle that can be either anti-inflammatory or proinflammatory, depending on its cargo of proteins, enzymes, and lipids. Some therapeutic approaches that reduce coronary risk, such as statins and therapeutic lifestyle changes, can favorably moderate the characteristics of proinflammatory HDL. In addition, apolipoprotein A-I mimetic peptides and other compounds that target functional aspects of HDL may offer novel approaches to reduction in cardiovascular risk. SUMMARY: Current data suggest that under some conditions HDL can become dysfunctional and even proinflammatory, but this characterization can change with resolution of systemic inflammation or use of certain treatments.
PURPOSE OF REVIEW: This review addresses how, in atherosclerosis or systemic inflammation, HDL can lose its usual atheroprotective characteristics and even paradoxically assume proinflammatory properties. RECENT FINDINGS: Specific chemical and structural changes within HDL particles can impede reverse cholesterol transport, enhance oxidation of LDL, and increase vascular inflammation. HDL may be viewed as a shuttle that can be either anti-inflammatory or proinflammatory, depending on its cargo of proteins, enzymes, and lipids. Some therapeutic approaches that reduce coronary risk, such as statins and therapeutic lifestyle changes, can favorably moderate the characteristics of proinflammatory HDL. In addition, apolipoprotein A-I mimetic peptides and other compounds that target functional aspects of HDL may offer novel approaches to reduction in cardiovascular risk. SUMMARY: Current data suggest that under some conditions HDL can become dysfunctional and even proinflammatory, but this characterization can change with resolution of systemic inflammation or use of certain treatments.
Authors: Theodoros Kelesidis; Judith S Currier; Diana Huynh; David Meriwether; Christina Charles-Schoeman; Srinivasa T Reddy; Alan M Fogelman; Mohamad Navab; Otto O Yang Journal: J Lipid Res Date: 2011-09-27 Impact factor: 5.922
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge Journal: J Am Soc Nephrol Date: 2015-08-28 Impact factor: 10.121
Authors: Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann Journal: J Am Soc Nephrol Date: 2012-01-26 Impact factor: 10.121
Authors: Chenghao Zhu; Lisa Sawrey-Kubicek; Elizabeth Beals; Riley L Hughes; Chris H Rhodes; Romina Sacchi; Angela M Zivkovic Journal: Metabolomics Date: 2019-08-17 Impact factor: 4.290
Authors: Nadeem Sarwar; Manjinder S Sandhu; Sally L Ricketts; Adam S Butterworth; Emanuele Di Angelantonio; S Matthijs Boekholdt; Willem Ouwehand; Hugh Watkins; Nilesh J Samani; Danish Saleheen; Debbie Lawlor; Muredach P Reilly; Aroon D Hingorani; Philippa J Talmud; John Danesh Journal: Lancet Date: 2010-05-08 Impact factor: 79.321
Authors: Sheung P Ng; Daniel J Conklin; Aruni Bhatnagar; Duane D Bolanowski; Jessica Lyon; Judith T Zelikoff Journal: Environ Health Perspect Date: 2009-04-13 Impact factor: 9.031